Safety and early effect of MatriPlax for ARDS
Part of Lungs & breathing clinical trials.
This trial tests an experimental drug called MatriPlax in people with moderate to severe ARDS caused by a virus. It aims to see if the drug is safe and if it can help improve breathing and recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have moderate to severe ARDS caused by a viral infection like COVID-19.
- You must be between 20 and 80 years old.
- You must be in the ICU and either on a breathing machine or ready to be put on one.
- The study drug must be given within 72 hours of your ARDS diagnosis.
- You must have stable vital signs (like blood pressure, heart rate, and temperature) within normal ranges.
- You must not have certain serious health conditions like severe liver or kidney disease, active cancer, or a history of blood clots.
- You must not be pregnant, nursing, or use certain hormonal birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This trial tests an experimental drug called R-3750 for people with a severe lung condition called ARDS that has not improved after at least a week. The drug is given through a tube into the stomach, and the goal is to see if it can help the lungs recover.
This trial tests a new treatment called IC14 for people in the hospital on a breathing machine for ARDS (a severe lung injury). The study aims to see if IC14, which blocks a protein involved in inflammation, can help the lungs heal faster.
This trial tests a new medicine (LEAF-4L6715) for people with acute respiratory distress syndrome (ARDS), a serious lung condition. The aim is to see if this medicine helps improve breathing and recovery in people on a breathing machine. The trial is for adults who have had ARDS for at least 24 hours and are already on a breathing machine.
This trial tests a new stem cell treatment made from umbilical cord cells for people with ARDS, a serious lung condition. The treatment may help reduce inflammation and improve lung function.
This Phase 3 trial studies an “extracellular vesicle” treatment in people with moderate to severe ARDS, a serious lung breathing problem. The goal is to see whether the treatment can improve outcomes compared with standard care.
Hear when a new Acute Respiratory Distress Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.